FERIVA 21-7 28-DAY- ascorbic acid, zinc glycinate, cyanocobalamin, ferrous asparto glycinate, folic acids and succinic acid tablet Trifluent Pharma, LLC

FeRiva 21/7 Rx Only Dietary Supplement

DESCRIPTION

FeRiva $21/7^{\$}$ 28-Day tablets for oral administration is a 28-day iron supplement regimen that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped placebo tablets. Each red, oval-shaped iron tablet is debossed with "21" and "7" separated by a line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped placebo tablet is blank on both sides of the tablet.

Supplement Facts Serving Size: 1 tablet		% Daily Value	% Daily Value for Pregnant & Lactating Women
Each Red Iron Tablet C	ontains:		
Vitamin C (as Ascorbic Acid)	175 mg	194%	146%
Zinc (as Zinc Bisglycinate)	10 mg	91%	77%
Vitamin B ₁₂ (as Cyanocobalamin)	12 mcg	500%	429%
Iron (as Ferrrous Asparto Glycinate) Sumalate®	75 mg	417%	278%
Folate (as ((6S)-N5- methyltetrahydrofolic acid calcium salt and folic acid)	1,667 mcg DFW (from 600 mcg L-%-MTHF-Ca and 400 mcg folic acid)	417%	278%
Succinic Acid	50 mg	†	†
† Daily Value (DV) not established.			

OTHER INGREDIENTS (RED IRON TABLETS)

Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide, and stearic acid. Coating contains: FD&C Red #40, HMPC, titanium dioxide and triacetin.

PURPLE PLACEBO TABLETS do not contain ANY vitamins, minerals, or other dietary ingredients. Please see OTHER INGREDIENTS section above for the listing of the inert ingredients.

INDICATIONS

FeRiva 21/7® 28-Day is a multivitamin/multimineral dietary supplement indicated for use

in improving the nutritional status of patients with iron deficiency.

CONTRAINDICATIONS

FeRiva 21/7 ® 28-Day is contraindicated in patients with a known hyper-sensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.

WARNING

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **KEEP THIS PRODUCT OUT OF REACH OF CHILDREN.** In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.

ADVERSE REACTIONS

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSAGE AND ADMINISTRATION

Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider.

The FeRiva $21/7^{\$}$ 28-Day tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple placebo tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple placebo tablet daily for 7 days. After 28 tablets have been taken a new course may be started if prescribed.

HOW SUPPLIED

FeRiva $21/7^{\$}$ 28-Day tablets blister pack (73352-318-28) contains of 21 red iron tablets and 7 purple placebo tablets. The listed product number is not a National Drug Code. Instead Trifluent Pharma has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.

Keep out of reach of children. Store between 20°- 25°C (68°- 77°F).

Sumalate® is a registered trademark of Albion Laboratories, Inc., covered by one or more claims of U.S. Patent Nos. 6,716,814, 8,007,846, and 8,425,956.

Distributed By:

Trifluent Pharma, LLC

San Antonio, TX 78213

Rev 01 04/25

PRINCIPAL DISPLAY PANEL - 28 tablet container label 73352-318-28 RX ONLY

FeRiva 21/7 28-Day Dietary Supplement



DIETARY SUPPLEMENT



FERIVA 21-7 28-DAY

ascorbic acid, zinc glycinate, cyanocobalamin, ferrous asparto glycinate, folic acids and succinic acid tablet

Product Information			
Product Type	DIETARY SUPPLEMENT	Item Code (Source)	NHRIC:73352-318
Route of Administration	ORAL		

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
ASCORBIC ACID (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R)	ASCORBIC ACID	175 mg		
ZINC GLYCINATE (UNII: 681VJX72FE) (ZINC CATION - UNII:13S1S8SF37)	ZINC GLYCINATE	10 mg		
CYANOCOBALAMIN (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204)	CYANOCOBALAMIN	12 ug		
FERROUS ASPARTO GLYCINATE (UNII: H7426RGB3L) (FERROUS CATION - UNII:GW895810WR)	FERROUS CATION	75 mg		
SUCCINIC ACID (UNII: AB6MNQ6J6L) (SUCCINIC ACID - UNII: AB6MNQ6J6L)	SUCCINIC ACID	50 mg		
FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8)	FOLIC ACID	1667 ug		

Inactive Ingredients			
Ingredient Name	Strength		
DICALCIUM PHOSPHATE (UNII: L11K75P92J)			
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)			
STEARIC ACID (UNII: 4ELV7Z65AP)			
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)			
MAGNESIUM STEARATE (UNII: 70097M6I30)			
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)			
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)			
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)			
TRIACETIN (UNII: XHX3C3X673)			
FD&C RED NO. 40 (UNII: WZB9127XOA)			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NHRIC:73352-318-28	28 in 1 CARTON		
1		1 in 1 BLISTER PACK		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
DIETARY SUPPLEMENT		04/18/2025	

Supplement Facts
Serving Size:

Serving per Container:

Amount Per Serving % Daily Value

color

color

scoring 1

shape

size (solid drugs) 7 mm

imprint

Labeler - Trifluent Pharma, LLC (117167281)

Establishment				
Name	Address	ID/FEI	Business Operations	
Avion Pharmaceuticals, LLC		040348516	manufacture(73352-318)	

Revised: 4/2025 Trifluent Pharma, LLC